Skip to site menu Skip to page content

Data Insights

Filter search results

By Company Name

No Filter Selected

By Disease Name

No Filter Selected

By Drug Name

No Filter Selected

By Themes
Showing 6 results out of 6

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

  • Gain a competitive edge
  • Enhance your sales strategy
  • Get forward-looking insights
  • Support your decision making
GlobalData

Buy Now
Data Insights

(Tipiracil hydrochloride + trifluridine) by Les Laboratoires Servier for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

(Tipiracil hydrochloride + trifluridine) is under clinical development by Les Laboratoires Servier and currently in Phase II for Human Epidermal...

Likelihood of Approval and Phase Transition Success Rate Model - (Tipiracil Hydrochloride + Trifluridine) in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)